Alkem is lined up to copy 5 of the blockbuster drugs on this tracker, which earned $26.7B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Alkem's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Entresto | Novartis | Generic | 2025 | FDA-approved 16 Sep 2024 | $7.7B |
| Xarelto | Bayer / Johnson & Johnson | Generic | 2025 | FDA-approved 26 Jun 2025 | ≈$5.3B |
| Farxiga | AstraZeneca | Generic | 2026 | FDA-approved 6 Apr 2026 | $8.4B |
| Otezla | Amgen | Generic | 2028 | FDA-approved 21 Sep 2021; settled 2021, terms confidential | $2.3B |
| Jakafi | Incyte | Generic | 2028 | Filed with the FDA; settled, terms confidential | $3.1B |
Company facts: Stock Analysis. Each drug page lists sources for these entries. Brand sales show the size of the market, not Alkem's share of it.
Alkem has FDA approval for Entresto, Farxiga, Otezla and Xarelto, with no US launch confirmed; and applications filed for Jakafi. It has settled with the brand owner over 2 drugs. Of the 70 makers we follow, 17 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.